Alto Ingredients Crecimiento futuro
Future controles de criterios 1/6
Se prevé un crecimiento anual de los beneficios y los ingresos de Alto Ingredients de 5.9% y 2.7% respectivamente, mientras que el BPA disminuirá en un 1.6% al año.
Información clave
5.9%
Tasa de crecimiento de los beneficios
-1.63%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Chemicals | 18.0% |
| Tasa de crecimiento de los ingresos | 2.7% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 07 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización del análisis • Apr 23
ALTO: MASH And Alcohol-Related Liver Programs Will Drive Future Upside Potential
Alto Ingredients' analyst fair value estimate has shifted from $4.00 to $6.75 as analysts factor in updated assumptions on discount rate, revenue growth, margins, and a higher future P/E in light of recent bullish coverage and revised price targets tied to pemvidutide's MASH and alcohol-related disease programs. Analyst Commentary Bullish Takeaways Bullish analysts are focused on pemvidutide as a differentiated asset for MASH and alcohol-related liver disease.
Actualización del análisis • Apr 09
ALTO: Future Returns Will Depend On MASH Trials And Alcohol Liver Data
Analysts have raised Alto Ingredients' price target to $25 from $12, citing pemvidutide's potential in MASH and alcohol-related liver and use disorders as key factors behind the revision. Analyst Commentary Recent Street research on Alto Ingredients highlights a mixed backdrop, with optimistic views on pemvidutide and the MASH program set against more cautious assessments of risk and valuation.Actualización del análisis • Mar 26
ALTO: Future Returns Will Hinge On MASH Trials And Funding Discipline
Analysts have raised their average price target for Alto Ingredients to $25 from $12, citing a sharpened focus on the planned MASH pivotal program and added potential value from pemvidutide in alcohol use disorder and alcohol liver disease, along with a solid cash runway and upcoming clinical catalysts. Analyst Commentary Recent Street research on Altimmune reflects a mix of optimism around the clinical pipeline and caution around execution risks and valuation.Actualización del análisis • Mar 11
ALTO: Future Returns Will Depend On Execution And Funding Discipline
Analysts have raised their price target on Alto Ingredients to $4.50 from $3.00, citing updated assumptions around fair value, discount rate, expected revenue growth, profit margins, and future P/E that they say are more in line with recent Street research on comparable companies. Analyst Commentary While the higher price target reflects updated valuation work, some bearish analysts in the broader small cap space are still emphasizing execution and funding risks that can weigh on sentiment for companies like Alto Ingredients.Actualización del análisis • Feb 25
ALTO: Future Upside Will Depend On Delivering Consistent Margin Execution
Analysts have adjusted their price target on Alto Ingredients to $3.00, with the neutral fair value and updated assumptions on discount rate, revenue growth, profit margin, and future P/E reflecting a refined view of the company’s risk and earnings profile following recent supportive research coverage. Analyst Commentary Recent research on Alto Ingredients has focused on reassessing the balance between potential upside and the risks tied to execution, earnings quality, and market conditions.Actualización del análisis • Feb 11
ALTO: Fair Outlook Will Rely On Sustaining Margins And Execution
Analysts have raised their price target for Alto Ingredients to US$3.00, reflecting updated views that include modestly higher revenue growth, slightly stronger profit margins, a lower discount rate, and a revised future P/E assumption, supported in part by recent bullish Street research. Analyst Commentary While the updated US$3.00 price target points to a more constructive stance overall, some bearish analysts remain cautious and continue to flag risk around how Alto Ingredients can justify this valuation through execution and earnings delivery.Actualización del análisis • Jan 27
ALTO: Upcoming Liver Meeting Data Will Support Repriced Risk Reward Profile
Analysts recently trimmed their 12 month price target on Alto Ingredients by US$1 to US$14, citing refreshed assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. Analyst Commentary Bearish analysts trimming price targets on comparable small cap names to around US$14, even when maintaining constructive ratings, suggest a tighter margin for error around assumptions such as discount rates, revenue growth, profit margins, and future P/E multiples.Actualización del análisis • Jan 12
ALTO: Upcoming Late-Stage Liver Data Will Support Repriced Risk Reward Profile
Narrative Update: Alto Ingredients Analyst Price Target Shift Analysts have trimmed their price target on Alto Ingredients by $1 to $14, citing updated risk and growth assumptions after the timing and outlook of recent clinical data were refined. Analyst Commentary Recent Street research reflects a more cautious tone, with bearish analysts trimming price targets and rechecking their assumptions on risk and potential upside.Actualización del análisis • Dec 26
ALTO: Upcoming Late-Stage Data Will Shape Risk Profile Amid Measured Outlook
Analysts have modestly lowered their price target on Alto Ingredients, trimming fair value by $1 to $14 as they factor in slightly softer long term assumptions, while remaining encouraged by upcoming late stage data presentations. Analyst Commentary Bearish analysts have pointed to the recent price target reduction to $14 as evidence that expectations for Alto Ingredients' long term growth and profitability are being tempered, even as upcoming late stage data remains a potential catalyst.Artículo de análisis • Dec 22
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Shares Leap 41% Yet They're Still Not Telling The Full Story
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 41% gain in the last month...Actualización del análisis • Dec 12
ALTO: Lower Discount Rate Will Support Improved Risk Profile Ahead
Analysts have raised their price target on Alto Ingredients by about $0.50, citing a lower perceived risk profile driven by a reduced discount rate, stronger expected revenue growth, and a modest improvement in projected profit margins and future valuation multiples. Analyst Commentary Bearish analysts remain cautious on Alto Ingredients despite the recent upward revision to the price target, emphasizing that the new target still embeds a meaningful discount to peers on key growth and profitability metrics.Artículo de análisis • Nov 07
Alto Ingredients, Inc. (NASDAQ:ALTO) Shares Fly 28% But Investors Aren't Buying For Growth
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 28% gain in the last month...Artículo de análisis • Jul 04
Alto Ingredients, Inc. (NASDAQ:ALTO) Held Back By Insufficient Growth Even After Shares Climb 31%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares have continued their recent momentum with a 31% gain in the last month...
Nuevo análisis • May 04
CO2 Plant Integration Will Boost Production And Exports
Acquisition and integration of the CO2 processing plant are expected to improve financials through cost synergies, increased capacity, and enhanced revenue streams.Artículo de análisis • Apr 22
Health Check: How Prudently Does Alto Ingredients (NASDAQ:ALTO) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Nov 12
Alto Ingredients (NASDAQ:ALTO) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Artículo de análisis • Jul 17
Alto Ingredients, Inc.'s (NASDAQ:ALTO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Alto Ingredients, Inc. ( NASDAQ:ALTO ) shareholders are no doubt pleased to see that the share price has bounced 26% in...Artículo de análisis • Jun 28
Would Alto Ingredients (NASDAQ:ALTO) Be Better Off With Less Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • Jan 15
Here's Why Alto Ingredients (NASDAQ:ALTO) Can Afford Some Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Artículo de análisis • Dec 20
Alto Ingredients, Inc. (NASDAQ:ALTO) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Those holding Alto Ingredients, Inc. ( NASDAQ:ALTO ) shares would be relieved that the share price has rebounded 25% in...Artículo de análisis • Sep 15
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Apr 10
We Think Alto Ingredients (NASDAQ:ALTO) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Artículo de análisis • Dec 16
Is Alto Ingredients (NASDAQ:ALTO) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Oct 19
Alto Ingredients: The Decline Has Created A Buying Opportunity
Summary Alto Ingredients has experienced some downward pressure over the past few months, even in spite of growing revenue and profits. Some of the bottom-line figures are deceptive given the role that a grant played in the matter, but the overall picture is still improving. Risk appears fairly low and shares look attractively priced right now. Just because an investment didn't offer attractive prospects at one point in time doesn't mean that the picture can't change for the better. As strong performance continues to be demonstrated and as shares of a company decline in price, the attractiveness of the firm in question can become more appealing, eventually reaching the point that assigning it a ‘buy’ rating just makes sense. One example of this can be seen by looking at Alto Ingredients (ALTO), a firm that produces and markets specialty alcohols and other essential ingredients for its customers. Recently, shares of the company have fallen even as fundamental performance remains strong. In addition to shares getting cheaper, the company continues to have cash in excess of debt totaling $22.2 million, leaving it with a good amount of wiggle room should market conditions worsen. Long term, investors should still expect significant volatility from a fundamental perspective. But given where shares are priced today, I do feel comfortable increasing my rating on the firm from a ‘hold’ to a ‘buy’, reflecting my opinion that the company’s stock should outperform the broader market for the foreseeable future. Robust strength changed my opinion Back in July of this year, I wrote an article that looked upon Alto Ingredients in a very neutral way. In truth, I was turned off by the volatility the company had seen in prior years, especially when it came to profitability. Having said that, profits in 2020 and 2021 proved to be rather robust for the company thanks to the change in market conditions. These changes, combined with a refusal by the market to push shares higher, leads into the stock looking rather cheap. But I still couldn't get over the company's business model and volatility as risk factors, ultimately resulting in a ‘hold’ rating for the business. Since then, shares of the firm have performed slightly better than I would have anticipated. While the S&P 500 has dropped by 12.9%, Alto Ingredients has seen a drop of 9.8%. Author - SEC EDGAR Data This return disparity is not necessarily large enough to be anything more than statistical noise. Having said that, it is also true that the company has continued to generate strong fundamental growth during this window of time. To see what I mean, we need only look at results covering the second quarter of the company's 2022 fiscal year. This is the only quarter for which data is now available that was not available when I last wrote about it. During that quarter, revenue came in at $362.2 million. That's 21.5% higher than the $298.1 million generated the same quarter only one year earlier. Total gallons of specialty alcohols the company sold actually dropped, declining from 125 million to 107.1 million. However, the firm did benefit from an increase in average pricing per gallon from $2.41 to $2.84. This drop in gallons sold was largely driven by a reduction in 3rd party gallons as the company continued to focus on the marketing and sales efforts associated with its own core production assets. The company also saw a more than doubling of sales of alcohol from its other production segment, driven by a rise in gallons sold of 14.4 million. This represents a 176% rise year over year. That unit also benefited from a $0.27 per gallon increase year over year. Meanwhile, essential ingredients revenue jumped by 221% to $23.4 million, driven by a 140% rise in volume and a 34% increase in average sales price per ton. Author - SEC EDGAR Data Clearly, the company's growth initiatives, particularly with regard to its emphasis on its own core production and to expanding into the specialty alcohols and essential ingredients spaces have proven to be beneficial for shareholders. The end result has also been an improvement in profitability. Net income in the second quarter of this year totaled $22.1 million. That's significantly higher than the $8.4 million reported one year earlier. Operating cash flow rose from $8.5 million to $9.6 million. But if we adjust for changes in working capital, the picture would have been even better, with the metric growing from $24.2 million to $38.4 million. Meanwhile, EBITDA also improved, rising from $17 million to $29.9 million. It is worth mentioning that profitability for the company was somewhat skewed. Although revenue has been rising, the firm benefited to the tune of $22.7 million from a grant associated with the USDA. Without that, operating income would have actually declined from $6.1 million in the second quarter of 2021 to negative $0.15 million the same time this year. It is worth mentioning that total results for the first half of the year did also come in stronger than what the company achieved in the first half of 2021. This much can be seen in the chart above. Author - SEC EDGAR Data Unfortunately, we don't really know what to expect for the rest of the current fiscal year. Given the one-time nature of the grant I mentioned, it's difficult to know what the organic potential the firm is. So instead of projecting out what results might look like for the rest of the year, I decided to price the company using data from 2021. Using this approach, the firm is trading at a price to adjusted operating cash flow multiple of 6.9 and at an EV to EBITDA multiple of 3.4. As part of my analysis, I compared the company to two other firms that are somewhat similar in nature. On a price to operating cash flow basis, these companies traded at multiples of 1.5 and 15.3. And using the EV to EBITDA approach, the multiples were 0.6 and 6.3. In both cases, our prospect was in the middle of the two.Seeking Alpha • Sep 12
Alto Ingredients gains on announcing $50M share repurchase program
Alto Ingredients (NASDAQ:ALTO) climbs on 4.76% premarket on authorizing share repurchase program for up to $ 50M of its common stock with an initial purchase authorization of $10M. “Given our positive long-term outlook, we believe our shares are currently undervalued. Based on the strength of our balance sheet, an opportunity exists to create value for our stockholders by repurchasing stock while we continue to upgrade our equipment and operating systems to increase efficiency and plant reliability, expand our corn storage capacity, enhance our specialty alcohol production, broaden our distribution, and reinvest in essential ingredients capabilities,” said Michael Kandris, CEO of Alto Ingredients.Artículo de análisis • Aug 31
Alto Ingredients (NASDAQ:ALTO) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Seeking Alpha • Jul 31
Alto Ingredients: Cheap For A Reason
Alto Ingredients has been all over the map in recent years, though profitability recently has been very encouraging. Shares of the business look cheap, but it's difficult to really compare it to other businesses. Given the obscurity associated with its business model and its volatility, the discount shares trade at are likely warranted. One fairly small but interesting company that investors should be aware of is Alto Ingredients (ALTO). Operationally speaking, the company has its hands in a couple of different areas that seem to be largely distinct from one another. But digging in deeper, you start to realize how these different spaces connect and, ultimately, make sense for the company to be involved in. Over an extended timeframe, the company's operating history has been quite lumpy, with some rather disappointing results. But even so, performance over the past two years has been somewhat promising. Add on top of this the fact that shares of the business do look to be rather cheap on an absolute basis, and it could be a decent prospect for some investors moving forward. But for me, there are better prospects to consider at this time, leading me to rate it a 'hold' until we have more clarity on what the new normal might look like. Understanding Alto Ingredients Based on its name alone, you might guess that Alto Ingredients focuses on some sort of ingredients or related products in the food business. To a large extent that is true. According to management, the company specializes in producing and marketing specialty alcohols and other essential ingredients, with the firm operating as the largest producer of specialty alcohols in the US. As of the end of the company's 2021 fiscal year, the firm boasted annual alcohol production capacity of 350 million gallons. This alcohol is produced from the five alcohol production facilities in its portfolio, with three of them located in Illinois and the other two split between Oregon and Idaho. Some discussion is warranted regarding the specifics of exactly what the company sells. For instance, in what management refers to as the health, home, and beauty category, the company markets specialty alcohols that are used in the production of mouthwash, cosmetics, pharmaceuticals, hand sanitizers, disinfectants, and cleaners. Under the food and beverage category, it produces specialty alcohols that are used in alcoholic beverages, flavor extracts, vinegar, and other related products. It also markets fuel-grade ethanol that's produced by both it and third parties, and it is responsible for the sale of 1.2 million tons of essential ingredients each year as well. On the fuel-grade ethanol side, the end use of the products the company sells includes transportation fuel and distillers corn oil that's used as biodiesel feedstock. And on the ingredients side, examples include dried yeast, corn gluten meal, corn gluten feed, and distillers grains and liquid feed that are used in commercial animal feed and pet foods. These items, management says, are co-products of its own alcohol production. To best understand the firm, we should probably break it up into the segments that it actually operates. The first of these is referred to as its Pekin Campus segment. This segment includes the company's production and sale of alcohols and essential ingredients that are produced at its Pekin, Illinois campus. Last year, this particular segment was responsible for 56.5% of the company's revenue. Next in line, we have the marketing and distribution segment, which includes its marketing and merchant trading for co-produced alcohols and essential ingredients, as well as the sale of third-party fuel-grade ethanol that it's involved in. This segment accounted for 32.1% of the firm's revenue last year. And finally, we have the 'other production' segment, which includes the company's production and sale of fuel-grade ethanol and essential ingredients that are produced at all of its other production facilities combined. But this was a fairly small portion of the enterprise last year, representing just 11.4% of its revenue. Over the past few years, the financial trajectory of the company has been less than ideal. Revenue actually dropped from 2017 through 2020, plunging from $1.63 billion to $897 million. It was only in 2021 that we saw something of a recovery, with revenue climbing to $1.21 billion for the year. This rise in revenue was driven by a number of factors. For instance, the company benefited from the average sales price per gallon of fuel-grade ethanol climbing by $0.83, or 51%, taking it from $1.63 per gallon to $2.46 per gallon. This was offset some by sales volume declining by 20 million gallons, or 11%, from 181 million gallons to 161 million gallons as a result of reduced production at its California facilities. These facilities were ultimately sold in 2021. The company also experienced a 1%, or roughly 1 million gallons, decline in sales volume associated with specialty alcohol production. Meanwhile, third-party sales volume of fuel-grade ethanol dropped by 35 million gallons, or 13%, from 264 million gallons in 2020 to 229 million gallons in 2021. However, this was planned by the company as the firm shifted from selling a lot of third-party fuel-grade ethanol so that I could focus more on sales of inventory of its own production. During this same time frame, the company also saw the total essential ingredients sold, as measured by tons, drop as well. The company went from selling 2.82 million tons in 2019 to just 1.24 million tons in 2021. However, pricing here happened to increase, just as we saw with the rise in gallons of fuel and alcohol sold. Author - SEC EDGAR Data Just like revenue, profitability for the company has also been rather volatile. Between 2017 and 2019, the company's net loss widened, going from $36.2 million to $90.2 million. The net last narrowed to $16.4 million in 2020 before turning to a profit of $44.2 million last year. As the chart above illustrates, other profitability metrics have also been all over the map. Perhaps the two most consistent though would be the adjusted operating cash flow figure and EBITDA. Operating cash flow, adjusted for changes in working capital, ultimately went from a negative $15.6 million in 2018 to a positive $40 million in 2021, while EBITDA turned from a negative $5.1 million to a positive $76.8 million over the same timeframe. Author - SEC EDGAR Data Performance for the company has been similarly volatile in the current fiscal year. In the first quarter, for instance, the company saw revenue come in at $308.1 million. That's 40.9% above the $218.7 million generated the same time one year earlier. This increase in revenue came even as the total gallons of fuel and alcohol decreased from 112 million in the first quarter of 2021 to 103.2 million this year. However, the company saw a 26.8% rise in average sales price per gallon that helped to make up for this. Most notably, the decline in product sold was actually driven by a 43.1% drop in 3rd party renewable fuel gallons sold. Specialty alcohol gallons rose by 22.6%, while renewable fuel gallons the company sold grew by 26.2%. And all of this increase came from the company's own facilities as it continues to make that transition away from relying on third parties and in the direction of benefiting from its own asset base. For anybody who follows the company closely, this should not be much of a surprise. In its latest quarterly report, the company listed a number of changes that it is making to its business. In February, for instance, the company expanded its portfolio of certifications by qualifying for two additional internationally recognized certifications at its Pekin Campus. It also launched its first project to produce enhanced protein at its dry mill in Magic Valley, Idaho using the patented CoProMax system that it plans to roll out at three other dry mills in the near future and at a total cost of $70 million. The company is currently expanding corn storage at its Pekin Campus property in order to increase its corn buying flexibility and to reduce its need to purchase product at premium prices when farmers and elevators have stopped shipping it for various reasons. The company has provided other examples of how it has changed its business model to prepare for the future. For instance, it is currently evaluating an investment that would bypass the local natural gas utility at its Pekin Campus that could result in the company reducing its natural gas prices by around 11%. Despite these improvements though, profitability metrics are still rather volatile for the year. In the first quarter, the company generated a net loss of $2.9 million. That compares to the $4.4 million profit achieved one year earlier. Operating cash flow went from a negative $4.5 million to a positive $11.1 million. But if we adjust for changes in working capital, it would have dropped from $2.3 million to negative $1.1 million. Meanwhile, EBITDA for the company also declined, falling from $13.4 million to $4.4 million. Author - SEC EDGAR Data All of this volatility and the uncertainty caused by recent investments by the company have made it impossible to know what the future might hold. But if we value the firm based on 2020 or 2021 results, shares do look rather cheap. The price to adjusted operating cash flow multiple should come in at 7.4 using our 2021 figures. That compares to the 8.5 reading that we get using 2020 results. Meanwhile, the EV to EBITDA multiple should be 3.9, which would be down from the 4.5 reading we get if we relied on 2020 figures. Now, unfortunately, because of the specific niche the company operates in, there aren't really any good firms to compare it to. Under the Peer section of the company page on Seeking Alpha, five companies related to the energy sector are listed as the most similar firms. Of these, only two had positive operating results. On a price to operating cash flow basis, these companies range from 2.1 to 8.9. And using the EV to EBITDA approach, the range was from 0.9 to 4.3. In both cases, Alto Ingredients was priced in the middle of the group.Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2027 | 963 | 30 | 41 | N/A | 2 |
| 12/31/2026 | 953 | 24 | 23 | N/A | 2 |
| 3/31/2026 | 916 | 28 | N/A | N/A | N/A |
| 12/31/2025 | 918 | 12 | 9 | 13 | N/A |
| 9/30/2025 | 922 | -51 | -10 | -6 | N/A |
| 6/30/2025 | 933 | -68 | -13 | -10 | N/A |
| 3/31/2025 | 951 | -60 | -30 | -23 | N/A |
| 12/31/2024 | 965 | -60 | -15 | -4 | N/A |
| 9/30/2024 | 1,003 | -37 | 3 | 18 | N/A |
| 6/30/2024 | 1,069 | -39 | 2 | 23 | N/A |
| 3/31/2024 | 1,150 | -28 | 22 | 47 | N/A |
| 12/31/2023 | 1,223 | -29 | -8 | 22 | N/A |
| 9/30/2023 | 1,278 | -43 | -23 | 14 | N/A |
| 6/30/2023 | 1,297 | -68 | -73 | -28 | N/A |
| 3/31/2023 | 1,341 | -53 | -73 | -28 | N/A |
| 12/31/2022 | 1,336 | -43 | -32 | 6 | N/A |
| 9/30/2022 | 1,393 | 26 | 19 | 48 | N/A |
| 6/30/2022 | 1,361 | 51 | 22 | 43 | N/A |
| 3/31/2022 | 1,297 | 37 | 28 | 42 | N/A |
| 12/31/2021 | 1,208 | 44 | 10 | 27 | N/A |
| 9/30/2021 | 991 | -12 | -37 | -24 | N/A |
| 6/30/2021 | 890 | 7 | 22 | 30 | N/A |
| 3/31/2021 | 804 | 13 | 31 | 40 | N/A |
| 12/31/2020 | 897 | -16 | 65 | 72 | N/A |
| 9/30/2020 | 1,086 | -37 | 74 | 80 | N/A |
| 6/30/2020 | 1,246 | -80 | 44 | 48 | N/A |
| 3/31/2020 | 1,380 | -102 | 15 | 19 | N/A |
| 12/31/2019 | 1,425 | -90 | N/A | -31 | N/A |
| 9/30/2019 | 1,402 | -81 | N/A | -52 | N/A |
| 6/30/2019 | 1,407 | -61 | N/A | -29 | N/A |
| 3/31/2019 | 1,471 | -67 | N/A | -22 | N/A |
| 12/31/2018 | 1,515 | -62 | N/A | 2 | N/A |
| 9/30/2018 | 1,576 | -43 | N/A | 28 | N/A |
| 6/30/2018 | 1,651 | -36 | N/A | 26 | N/A |
| 3/31/2018 | 1,646 | -31 | N/A | 33 | N/A |
| 12/31/2017 | 1,632 | -36 | N/A | 37 | N/A |
| 9/30/2017 | 1,679 | -10 | N/A | 57 | N/A |
| 6/30/2017 | 1,651 | -13 | N/A | 51 | N/A |
| 3/31/2017 | 1,669 | 1 | N/A | 54 | N/A |
| 12/31/2016 | 1,625 | 0 | N/A | 37 | N/A |
| 9/30/2016 | 1,560 | -14 | N/A | 6 | N/A |
| 6/30/2016 | 1,523 | -25 | N/A | -37 | N/A |
| 3/31/2016 | 1,327 | -29 | N/A | -39 | N/A |
| 12/31/2015 | 1,191 | -20 | N/A | -28 | N/A |
| 9/30/2015 | 1,071 | -7 | N/A | -5 | N/A |
| 6/30/2015 | 966 | 11 | N/A | 48 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (5.9% al año) de ALTO es superior a la tasa de ahorro (3.5%).
Beneficios vs. Mercado: Se prevé que los beneficios (5.9% al año) de ALTO crezcan menos que el mercado US (16.4% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de ALTO crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (2.7% al año) de ALTO crezcan más despacio que el mercado de US (11.4% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 2.7% al año) de ALTO crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de ALTO se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/07 12:16 |
| Precio de las acciones al final del día | 2026/05/07 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Alto Ingredients, Inc. está cubierta por 9 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Carter Driscoll | B. Riley Securities, Inc. |
| Hamed Khorsand | BWS Financial Inc. |
| Eric Stine | Craig-Hallum Capital Group LLC |